Some clinical studies have shown responses to PD‐1 blockade in patients with PD‐L1 expression on tumor cells or on tumor‐infiltrating immune cells.22, 23 As patients with nPD‐L1+ iDLBCL are characterized by an aggressive clinical course in the rituximab era, they represent good candidates for novel therapies that enhance antitumor immune responses. Here, CD274 is linked to neoplasm.